Company Overview of Ludwig Institute for Cancer Research Ltd.
Ludwig Institute for Cancer Research Ltd., a non-profit research institute, focuses to improve the understanding and control of cancer. Its activities include investigator-initiated work to understand how and why cancer onset and progression occur; and exploring the prognostic, diagnostic, and/or therapeutic potential of its discoveries by conducting clinical research in the human setting. The company also engages in exploring therapeutic modalities that include cancer vaccines, targeted antibodies, enzymatic depletion, small molecule inhibitors, and siRNAs. Ludwig Institute for Cancer Research Ltd. was founded in 1971 and is based in New York, New York. It has research sites in Brussels, Be...
605 Third Avenue
New York, NY 10017
Founded in 1971
Key Executives for Ludwig Institute for Cancer Research Ltd.
Chief Financial Officer and Secretary
Executive Director of Operations
Executive Director of Technology Development
Director of Communications
Compensation as of Fiscal Year 2014.
Ludwig Institute for Cancer Research Ltd. Key Developments
4-Antibody AG Enters into License Agreement with Ludwig Institute for Cancer Research Ltd
Dec 11 14
4-Antibody AG entered into a License Agreement with the Ludwig Institute for Cancer Research Ltd. which replaces and supersedes the Collaborative Research and Development Agreement entered into between the parties on May 23, 2011. Pursuant to the terms of the License Agreement, Ludwig granted 4AB an exclusive, worldwide license under certain intellectual property rights of Ludwig and Memorial Sloan Kettering Cancer Center arising from the Prior Agreement to further develop and commercialize GITR, OX-40 and TIM-3 antibodies. Pursuant to the License Agreement, 4AB is obligated to make an upfront payment of $1 million to Ludwig. The License Agreement also obligates 4AB to make potential milestone payments of up to $20 million for events prior to regulatory approval of licensed products, and potential milestone payments in excess of $80 million if licensed products are approved in multiple jurisdictions, in more than one indication, and certain sales milestones are achieved. 4AB will also be obligated to pay low to mid-single digit royalties on all net sales of licensed products during the royalty period, and to pay Ludwig a percentage of any sublicensing income, ranging from a low to mid-double digit percentage depending on various factors. The License Agreement may be terminated as follows: by either party if the other party commits a material, uncured breach; by either party if the other party initiates bankruptcy, liquidation or similar proceedings; or by 4AB for convenience upon 90 days' prior written notice.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries